The New Jersey-based pharma has inked one of the biggest deals of the year in pursuit of a promising new way to treat COPD.
|
The agency disclosed a tranche of more than 200 complete response letters from the past five years, but only those involving medicines that it later cleared.
|
The biotech is taking inspiration from cystic fibrosis treatment and applying a similar approach to developing "corrector" and "potentiator" medicines for the kidney disease.
|
While Trump indicated drug levies would be set at a “very high” rate, he added that pharma firms would first be given time to bring manufacturing to the U.S.
|
The deal hands AbbVie a drug that’s shown early promise in multiple myeloma and may be useful treating other cancers and autoimmune conditions, too.
|
Recommended For You
Improve your recommendations: click here to update your profile.
Deep Dive
Some two dozen biotech developers of PROTACs, molecular glues and other types of protein-degrading drugs have sprung up over the past two decades.
|
Improve launch success and optimize investments
|
|
From Our Library
Trendline
Supported by Quest Diagnostics
|
Trendline
Supported by Marken
|
View all resources
Best of What We're Reading
Bloomberg
|
| 
